Why Arcellx (ACLX) Stock Is Nosediving
Portfolio Pulse from Henry Khederian
Arcellx Inc's (ACLX) stock is down 8.50% after the FDA placed a clinical hold on the company's multiple myeloma phase 2 trial due to a patient death. Arcellx is working with the FDA to expand patient options and is confident in CART-ddBCMA as a potential leading therapy for rrMM.
June 20, 2023 | 2:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arcellx's stock is down 8.50% after the FDA placed a clinical hold on its multiple myeloma phase 2 trial. The company is working to resolve the issue and remains confident in its therapy.
The FDA's clinical hold on Arcellx's multiple myeloma phase 2 trial has caused the stock to drop significantly. This is a major setback for the company, but they are working to resolve the issue and remain confident in their therapy. The stock is likely to be negatively impacted in the short term due to this news.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100